A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS)-Reference-Cited by-同舟云学术

A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS)

Published:2023-08-18 Issue:12 Volume:34 Page:2047-2058
ISSN:0937-941X
Container-title:Osteoporosis International
language:en
Short-container-title:Osteoporos Int

Author:

Shi X.,Cheng Q.,Zhao Y.-Z.,Zou S.-P.,Sun M.-H.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s00198-023-06877-6.pdf

Reference27 articles.

1. Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ (2016) Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157:141–149

2. Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 317(4):722–733

3. Tymlos [package insert] (2018) Waltham, MA: Radius Health, Inc; https://www.accessdata.fda.gov/drugsatfda_docs/Label/2018/208743s003lbl.pdfAccessed June 10, 2019

4. Esbrit P, Herrera S, Portal-Núñez S, Nogués X, Díez-Pérez A (2016) Parathyroid hormone-related protein analogs as osteoporosis therapies. Calcif Tissue Int 98(4):359–369

5. Miller PD, Hattersley G, Riis BJ, ACTIVE Study Investigators et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722–733

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases;Frontiers in Pharmacology;2024-07-04

2. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database;Frontiers in Pharmacology;2024-02-16

3. Vonoprazan-associated Clostridioides difficile infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System;Therapeutic Advances in Drug Safety;2024-01

4. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS);BMC Pharmacology and Toxicology;2023-11-13